Commercialization of rare & orphan products in Switzerland and smaller EU Markets
Unlocking economic opportunities: commercializing rare & orphan products in Switzerland and beyond the EU’s big five
Rare and orphan diseases present significant challenges and opportunities for healthcare systems worldwide, but recent developments in Switzerland and the smaller EU markets have led to new opportunities.
In this paper we cover:
- How recent policy changes are making market access more difficult for orphan drugs.
- How Switzerland’s position as the third-fastest country for reimbursing new medicines post-approval, coupled with its simplified authorization procedure, make it an attractive market for biotech companies.
- The diverse types of access programs available in Switzerland and the EU.
- The unique opportunities for orphan drug commercialization in Switzerland and other smaller EU markets.
Download this paper for actionable insights to help navigate the complex commercialization landscape for orphan drugs in Switzerland and the smaller EU markets.
About Sciensus
Sciensus is a European leader in integrated end-to-end commercial services, supporting patients, health systems, providers and biopharma companies. We offer distribution services, clinical care at home, digital solutions and patient insights to accelerate access to medicines and maximise product launches from clinical to full commercialisation. With over 30 years’ experience navigating the complex European healthcare ecosystem, Sciensus helps bring the right medicine to the right patients – faster.
